Creative Planning’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,978
| Closed | -$356K | – | 2057 |
|
|
2017
Q3 | $356K | Sell |
1,978
-5,141
| -72% | -$716K | ﹤0.01% | 1231 |
|
|
2017
Q2 | $738K | Buy |
7,119
+4,275
| +150% | +$349K | ﹤0.01% | 828 |
|
|
2017
Q1 | $223K | Sell |
2,844
-10,363
| -78% | -$641K | ﹤0.01% | 1424 |
|
|
2016
Q4 | $592K | Sell |
13,207
-4,586
| -26% | -$225K | ﹤0.01% | 852 |
|
|
2016
Q3 | $994K | Sell |
17,793
-2,422
| -12% | -$135K | 0.01% | 594 |
|
|
2016
Q2 | $1.01M | Buy |
20,215
+2,030
| +11% | +$99.7K | 0.01% | 520 |
|
|
2016
Q1 | $835K | Buy |
18,185
+3,510
| +24% | +$170K | 0.01% | 553 |
|
|
2015
Q4 | $904K | Sell |
14,675
-885
| -6% | -$62.3K | 0.01% | 531 |
|
|
2015
Q3 | $866K | Buy |
15,560
+1,902
| +14% | +$120K | 0.01% | 522 |
|
|
2015
Q2 | $833K | Buy |
+13,658
| New | +$779K | 0.01% | 522 |
|
|
2015
Q1 | – | Sell |
-27,080
| Closed | -$1.81M | – | 4530 |
|
|
2014
Q4 | $1.56M | Buy |
+27,080
| New | +$1.14M | 0.02% | 332 |
|
Creative Planning's KITE Position: Q4 2017 in Review
Creative Planning sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 1,978 shares — an estimated $356K sold.
Creative Planning first reported a position in KITE in Q4 2014 and held it in 11 quarters. The position peaked at $1.56M in Q4 2014. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Creative Planning reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Creative Planning sold 1,978 Kite Pharma, Inc. shares in Q4 2017, an estimated $356K.
- Creative Planning first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 11 quarters.
- Creative Planning's Kite Pharma, Inc. position peaked at $1.56M in Q4 2014.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Creative Planning's 13F filing for Q4 2017, filed 17 Jan 2018.